ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements with these filters
Sudarshan Pharma approved raising up to ₹191.86 Crore through Foreign Currency Convertible Bonds. This fund-raise strengthens the company's capital base for future growth and operations.
Sudarshan Pharma scheduled a board meeting for May 15, 2026, to consider issuing Foreign Currency Convertible Bonds. The proposal remains subject to regulatory and statutory approvals.
Mr. Sachin Mehta resigned as Chief Financial Officer effective May 1, 2026. He will continue serving as the company's Joint Managing Director.
Mr. Sachin Mehta has resigned as Chief Financial Officer of Sudarshan Pharma Industries Ltd, effective May 1, 2026. He will continue to serve the company in his capacity as Joint Managing Director. This transition represents a focused leadership adjustment within the organization's senior management structure.
Sudarshan Pharma Industries Ltd appointed Mr. Sanat Bhat (Independent Director), Dr. Vinay Pandey (Non-Executive Director), and Mr. Sharad Govindrao Kathawate (CFO) effective May 1, 2026. These leadership changes bring expertise in finance, infrastructure, and geotechnical engineering to the board and management team.
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹220.9 Cr (+36.7% YoY) and net profit of ₹11.4 Cr (+54.1% YoY) for Q4 FY26.
Sudarshan Pharma Industries Ltd reported consolidated total income of ₹711.77 Crore for the financial year ended March 31, 2026. Consolidated net profit reached ₹23.30 Crore, up from ₹14.97 Crore in the previous year. The company successfully transitioned to Ind AS reporting during the period, reflecting strong operational growth and expanded financial transparency.
Sudarshan Pharma Industries Ltd has scheduled a Board Meeting on April 30, 2026. The board will consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's trading window remains closed for 48 hours post-declaration.
Sudarshan Pharma Industries Ltd reported net profit of ₹4.1 Cr (+41.4% YoY) for Q3 FY26.